Hong I. Wan, Ph.D., Scientific Advisor

Dr. Wan currently serves as the Chief Scientific Officer at ALX Oncology. She previously served as Senior Director, Biotechnology Clinical Development at Rinat (Pfizer), where she was responsible for the early development and translational medicine strategy across various therapeutic areas. Prior to that, Dr. Wan held positions as Director, Translational and Molecular Medicine at Pfizer and Director, Clinical Translational Medicine at Wyeth. Before joining Wyeth, Dr. Wan was Project Lead and Senior Scientist at Renovis.

Education:

Ph.D. in Molecular and Cell Biology from University of California, Berkeley
A.B. in Biochemical Sciences from Harvard University

Sector: Biopharmaceuticals

Location: Menlo Park

 
See other team members.